neisseria gonorrhoeae strain fa1090 a26
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 10, 2013 (NCT04870138)
Timeline
Indications
Studied for
Mechanism of action
- Neisseria gonorrhoeaeImmunity, active
Neisseria gonorrhoeae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05294588 | Phase 2 | Apr 18, 2022 | National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT03840811 | Phase 1 | Apr 23, 2017 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04870138 | Phase 1 | Mar 10, 2013 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 2 | 2 | 2013 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1